(Q38814097)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26640245%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26640245%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26640245%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Elke Hattingen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26640245%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Patrick N. Harter

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26640245%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Jörg Steinbach

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26640245%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Congcong Zhang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26640245%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Michael C Burger

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26640245%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Sabrina Genßler

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26640245%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Kurt Schönfeld

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26640245%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Pia Zeiner

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26640245%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Torsten Tonn

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26640245%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Winfried S Wels

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26640245%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Michel Mittelbronn

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26640245%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

language of work or name

English

0 references

publication date

6 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26640245%20AND%20SRC:MED&resulttype=core&format=json

Journal of the National Cancer Institute

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26640245%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

108

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26640245%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26640245%20AND%20SRC:MED&resulttype=core&format=json

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Very late relapses in glioblastoma long-term survivors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Glioblastoma and other malignant gliomas: a clinical review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Presence and significance of NK cells in glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta 2 inhibits the generation of lymphokine-activated killer (LAK) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

NK cells recognize and kill human glioblastoma cells with stem cell-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Use of allogeneic NK cells for cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Treatment of patients with advanced cancer with the natural killer cell line NK-92.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Amplification and differential expression of members of the erbB-gene family in human glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Focused ultrasound delivers targeted immune cells to metastatic brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Radiographic patterns of relapse in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Natural killer-dendritic cell cross-talk in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Natural-killer cells and dendritic cells: "l'union fait la force".

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

21 January 2018

Cancer genome landscapes

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV375

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJV375

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26640245%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference